EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Switching From Standard to Extended Half‐Life Coagulation Factor Replacement in Haemophilia: Clinical Outcomes and Costs of Care in Finland

Mirkka Koivusalo, Timea Szanto iD, Tuomas Kovalainen, Aino Vesikansa iD, Outi Laine, Anu Partanen, Timo Siitonen, Marko Vesanen, Juha Mehtälä, Nina Sarnesto, Johanna Haapkylä, Anna-Elina Lehtinen und 1 weitere

Haemophilia · 2025

DOI: 10.1111/hae.70067 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2025. Verfasst von Mirkka Koivusalo und 12 weiteren Autor:innen. Beteiligte Einrichtung: MedEngine Oy, Helsinki, Finland. Hauptthemen laut MEDLINE: Hemophilia A, Blood Coagulation Factors, Health Care Costs. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Real‐world data are needed to evaluate treatment implementation, outcomes and costs of care in haemophilia patients switching prophylaxis from standard half‐life (SHL) to extended half‐life (EHL) clotting factor concentrates (CFCs).

Aim

We characterised treatment regimens, annual bleeding rate (ABR), adherence and costs in a nationwide Finnish haemophilia A (HA) and B (HB) cohort on prophylaxis, including non‐switchers and switchers from SHL to EHL CFC.

Methods

This retrospective register study of adult patients with HA and HB was performed in University Hospitals during 2016–2021. Clinical and healthcare data were captured from electronic health records and national healthcare registers.

Results

Majority, 74% of HA and 71% of HB patients, switched from SHL to EHL. Thereafter, weekly mean infusions of CFC decreased (FVIII SHL 2.8, EHL 2.2; FIX SHL 1.6, EHL 0.9; p < 0.001). The mean annual consumption (international units, IU) increased by 18% from 219,534 per HA patient during SHL to 258,317 during EHL ( p < 0.05) and declined per HB patient by 28% from 221,685 to 160,209 ( p < 0.01). ABR appeared to decline after the switch in HA (mean SHL 2.8, EHL 0.9) and HB (SHL 1.6, EHL 0.8), while treatment adherence improved in HA from 81% to 95% ( p < 0.01). The mean annual total costs of care in HA were €176,979 for SHL and €195,760 for EHL. In HB, the costs increased from €180,930 to €236,208 ( p < 0.01).

Conclusions

Majority of patients on prophylaxis switched to EHL. The switch alleviated the infusion regimen, tended to lower bleeding rates and improved adherence with somewhat increased costs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia ABlood Coagulation FactorsHealth Care CostsHumansFinlandMaleAdultRetrospective StudiesMiddle AgedHalf-LifeTreatment OutcomeFemaleYoung AdultAdolescent

Stichwörter der Autor:innen

adherenceannual bleeding ratecoagulation factor consumptioncosthaemophiliaprophylaxis

Substanzen

Blood Coagulation Factors

Autor:innen und Institutionen

  • MedEngine Oy, Helsinki, Finland.
  • Department of Hematology, Comprehensive Cancer Center, Coagulation Disorders Unit, Helsinki University Hospital, Helsinki, Finland.
  • Research Program Unit in Systems Oncology, University of Helsinki, Helsinki, Finland.
  • Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.
  • Department of Medicine, Kuopio University Hospital, Kuopio, Finland.
  • Department of Medicine, Oulu University Hospital, Oulu, Finland.

ORCID-Profile: Timea Szanto, Aino Vesikansa, Riitta Lassila

Förderung

  • Novo Nordisk Pharma

Zitieren

APA

Koivusalo, M., Szanto, T., Kovalainen, T., Vesikansa, A., Laine, O., Partanen, A., Siitonen, T., Vesanen, M., Mehtälä, J., Sarnesto, N., Haapkylä, J., Lehtinen, A. E., & Lassila, R. (2025). Switching From Standard to Extended Half‐Life Coagulation Factor Replacement in Haemophilia: Clinical Outcomes and Costs of Care in Finland. Haemophilia. https://doi.org/10.1111/hae.70067

Vancouver

Koivusalo M, Szanto T, Kovalainen T, Vesikansa A, Laine O, Partanen A, et al. Switching From Standard to Extended Half‐Life Coagulation Factor Replacement in Haemophilia: Clinical Outcomes and Costs of Care in Finland. Haemophilia. 2025. doi:10.1111/hae.70067

BibTeX
@article{Koivusalo2025,
  author = {Koivusalo, Mirkka and Szanto, Timea and Kovalainen, Tuomas and Vesikansa, Aino and Laine, Outi and Partanen, Anu and Siitonen, Timo and Vesanen, Marko and Mehtälä, Juha and Sarnesto, Nina and Haapkylä, Johanna and Lehtinen, Anna-Elina and Lassila, Riitta},
  title = {Switching From Standard to Extended Half‐Life Coagulation Factor Replacement in Haemophilia: Clinical Outcomes and Costs of Care in Finland},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.70067}
}
Kostenlos starten →